PBH Stock Overview
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Prestige Consumer Healthcare Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$70.14 |
52 Week High | US$75.31 |
52 Week Low | US$52.90 |
Beta | 0.53 |
1 Month Change | -2.58% |
3 Month Change | 11.44% |
1 Year Change | 13.50% |
3 Year Change | 59.08% |
5 Year Change | 138.49% |
Change since IPO | 295.15% |
Recent News & Updates
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Recent updates
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Feb 11Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon
Feb 05Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Dec 14Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Sep 10Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation
Aug 15Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?
Jun 12An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued
May 20Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors
Mar 17Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 02Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price
Feb 08Prestige Consumer Healthcare reports Q3 earnings beat; updates FY23 guidance
Feb 02Prestige Consumer Healthcare: Taking My Winnings Off The Table
Jan 19Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Nov 23Prestige Consumer Healthcare GAAP EPS of $1.02 beats by $0.02, revenue of $289.3M beats by $6.07M
Nov 03Holding Prestige Consumer Healthcare
Aug 31If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity
Aug 26We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Aug 05Prestige Consumer Healthcare GAAP EPS of $1.09 beats by $0.05, revenue of $277.1M beats by $8.18M
Aug 04Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?
May 27Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
May 05Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?
Feb 22Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
Feb 03These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Nov 04Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has A Meaningful Debt Burden
Aug 06Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jun 14Prestige Consumer Healthcare Inc. 2021 Q4 - Results - Earnings Call Presentation
May 08These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Apr 19How Much Did Prestige Consumer Healthcare's (NYSE:PBH) CEO Pocket Last Year?
Feb 22Shareholder Returns
PBH | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 2.6% | -0.6% | 1.0% |
1Y | 13.5% | 10.6% | 21.9% |
Return vs Industry: PBH matched the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: PBH underperformed the US Market which returned 24.9% over the past year.
Price Volatility
PBH volatility | |
---|---|
PBH Average Weekly Movement | 3.6% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PBH has not had significant price volatility in the past 3 months.
Volatility Over Time: PBH's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 560 | Ron Lombardi | www.prestigebrands.com |
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief.
Prestige Consumer Healthcare Inc. Fundamentals Summary
PBH fundamental statistics | |
---|---|
Market cap | US$3.48b |
Earnings (TTM) | -US$80.67m |
Revenue (TTM) | US$1.13b |
3.1x
P/S Ratio-43.2x
P/E RatioIs PBH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PBH income statement (TTM) | |
---|---|
Revenue | US$1.13b |
Cost of Revenue | US$500.02m |
Gross Profit | US$634.21m |
Other Expenses | US$714.88m |
Earnings | -US$80.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | -1.62 |
Gross Margin | 55.92% |
Net Profit Margin | -7.11% |
Debt/Equity Ratio | 74.9% |
How did PBH perform over the long term?
See historical performance and comparison